Immuneering (NASDAQ:IMRX) Issues Earnings Results

Immuneering (NASDAQ:IMRX) announced its quarterly earnings data on Wednesday. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01), FiscalAI reports.

Immuneering Trading Down 1.0%

NASDAQ:IMRX traded down $0.04 during mid-day trading on Wednesday, reaching $4.36. 259,348 shares of the stock were exchanged, compared to its average volume of 1,435,640. The business has a fifty day moving average price of $4.62 and a 200 day moving average price of $4.99. The firm has a market capitalization of $281.77 million, a PE ratio of -3.71 and a beta of 0.43. Immuneering has a 1-year low of $2.90 and a 1-year high of $10.08.

Hedge Funds Weigh In On Immuneering

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC grew its holdings in shares of Immuneering by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after purchasing an additional 4,458 shares during the last quarter. Southport Management L.L.C. raised its position in shares of Immuneering by 1.8% in the 4th quarter. Southport Management L.L.C. now owns 277,501 shares of the company’s stock worth $1,826,000 after acquiring an additional 5,000 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Immuneering by 46.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock valued at $137,000 after buying an additional 6,196 shares in the last quarter. LPL Financial LLC increased its holdings in Immuneering by 30.0% in the 4th quarter. LPL Financial LLC now owns 29,125 shares of the company’s stock worth $192,000 after acquiring an additional 6,725 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of Immuneering in the 3rd quarter worth $70,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on IMRX shares. Needham & Company LLC upped their target price on shares of Immuneering from $11.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Oppenheimer reaffirmed an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. Wall Street Zen downgraded shares of Immuneering from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a report on Wednesday, June 24th. Finally, Chardan Capital reissued a “buy” rating and issued a $20.00 price objective on shares of Immuneering in a research report on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $17.57.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.